← All Abbott Laboratories filings

Abbott Laboratories 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
ABT
Abbott Laboratories
10-K: Abbott Laboratories Reports Strong Growth in 2024, Driven by Medical Devices and Nutritional Products
Abbott Laboratories' 2024 10-K filing reveals revenue growth driven by Medical Devices, Established Pharmaceuticals, and Nutritional Products, despite a decline in COVID-19 testing-related sales.
NYSE
ABT
Abbott Laboratories
10-K: Abbott Secures $5 Billion Credit Line, Enhances Financial Flexibility
Abbott Laboratories has entered into a new five-year credit agreement for $5 billion, replacing its previous facility and bolstering its financial position.